Pexmetinib

DB16294InvestigationalSmall molecule

Pexmetinib is under investigation in clinical trial NCT04074967 (Study of ARRY-614 Plus Either Nivolumab or Ipilimumab).

Mechanism: Pharmacologically active on Mitogen-activated protein kinase 14 and Angiopoietin-1 receptor
Curator reviewed
Formula / weight: C₃₁H₃₃FN₆O₃ · 556.642 g/mol (avg)
Code names: ARRY-614

Resolves to

Compound

Structure

InChIKeyLNMRSSIMGCDUTP-UHFFFAOYSA-NSMILESCC1=CC=C(C=C1)N1N=C(C=C1NC(=O)NCC1=CC(F)=CC=C1OC1=CC2=C(C=C1)N(CCO)N=C2)C(C)(C)C

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pexmetinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.